|
Market Cap (10-Jun) $47,863,656 (0th) |
Close (30-Jun) $0.85 |
Volume (30-Jun) 942,590 |
Shortsold (27-Oct) 800,001 (0.58%) (257th) |
|
52w High $0.490 |
52w Low $0.312 |
P/E - |
EPS -0.06 |
IIQ released this announcement to the ASX on 31 January 2022, 16:30. The announcement is not marked as price sensitive, and is 6 page(s) in length and 25.09kb in size.
You can view all announcements from IIQ and see how they appear on a price chart on the announcements page.
At the date of this announcement, IIQ was 0.002% short sold according to ASIC data. It was ranked the 733rd most shorted stock on the ASX. It is now ranked as the 257th most shorted stock on the ASX with 0.576% of total shares short sold as of the latest reported data (27 October 2025).
| Other Recent Announcements from IIQ | |
|---|---|
| Notification of cessation of securities - IIQ | 30 June 2023, 14:19 |
| SubB2M/CA15.3 Clinical Validation Data Investor Presentation | 29 June 2023, 10:48 |
| INOVIQ Investor Briefing | 27 June 2023, 14:07 |
| Notification regarding unquoted securities - IIQ | 31 January 2022, 16:30 |
| Appendix 4C & Quarterly Activities Report | 31 January 2022, 10:13 |
| US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis | 17 January 2022, 8:48 |
| INOVIQ Awarded Additional BTB Funding to Develop SubB2M test | 10 January 2022, 8:59 |
You must be logged in to post a reply.
